** Shares of drug developer INmune Bio INMB.O fall 6.49% to $2.16 in premarket trading
** Scotiabank downgrades stock to 'sector underperform' from 'sector outperform'
** Slashes PT to $0.60 from $23; an 89% downside to the stock's last close at $5.33
** Brokerage cites failure of lead drug XPro, which targets a protein linked to inflammation, to show any health improvements in a study on patients with Alzheimer's disease
** On Monday, co said the experimental drug failed to improve cognitive function in early-stage patients during a mid-stage trial
** Co plans to file for FDA breakthrough therapy designation and schedule an End-of-Phase 2 meeting with the health regulator in Q4 2025
** Brokerage also added that INmune has a very low chance of getting FDA approval for its drug CORDStrom to treat recessive dystrophic epidermolysis bullosa (RDEB) a rare skin disease
** Average rating of 5 analysts is "buy"; median PT is $20.5 — data compiled by LSEG
** As of last close, stock down ~50.53% YTD
(Reporting by Akriti Shah in Bengaluru)
((akriti.shah@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。